Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020139984 - IGG FC VARIANTS FOR VETERINARY USE

Publication Number WO/2020/139984
Publication Date 02.07.2020
International Application No. PCT/US2019/068629
International Filing Date 26.12.2019
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 15/62 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
CPC
A61K 2039/552
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
55characterised by the host/recipient, e.g. newborn with maternal antibodies
552Veterinary vaccine
C07K 14/605
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
605Glucagons
C07K 14/7155
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
715for cytokines; for lymphokines; for interferons
7155for interleukins [IL]
C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C07K 2317/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
Applicants
  • KINDRED BIOSCIENCES, INC. [US]/[US]
Inventors
  • ZHAN, Hangjun
  • NGUYEN, Lam
  • LI, Yongzhong
  • QIAN, Fawn
  • LI, Shyr, Jiann
  • CHIN, Richard
Agents
  • HENNINGER, Mary, R.
  • SCARR, Rebecca
  • BAUR, Amelia
  • MCNEILL, Rebecca
  • DOHERTY, Elizabeth
  • BREIER, Adam
  • LEE, Victoria
  • PRYBYLOWSKI, Kate
  • KELLEY, Lara
  • HERZFELD, Deborah
  • SCHOENHARD, Amy
  • CHO, Hojung
  • CISAR, Elizabeth
  • MCELHONE, Katharine
  • LANG, Hilary
Priority Data
62/785,68027.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IGG FC VARIANTS FOR VETERINARY USE
(FR) VARIANTS D'IGG FC À USAGE VÉTÉRINAIRE
Abstract
(EN)
Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased Clq binding for reduced complement-mediated immune responses, decreased CD 16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction), increased stability, and/or the ability to form multimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. In various embodiments, such polypeptides may be used to treat companion animals, such as canines, felines, and equines.
(FR)
L'invention concerne divers modes de réalisation relatifs à des polypeptides d'IgG Fc variants d'animaux de compagnie ayant une fixation de protéine A accrue pour une purification aisée, une fixation de C1q réduite pour des réponses immunitaires à médiation par le complément réduites, une fixation de CD16 réduite (par exemple, pour une induction de cytotoxicité cellulaire dépendante des anticorps (ADCC) réduite, une stabilité accrue et/ou la capacité de former des protéines hétérodimères). De plus, divers modes de réalisation se rapportant à des anticorps et à des protéines de fusion comprenant de tels polypeptides d'IgG Fc variants sont décrits. Dans divers modes de réalisation, de tels polypeptides peuvent être utilisés pour traiter des animaux de compagnie, tels que des canidés, des félins et des équidés.
Also published as
Latest bibliographic data on file with the International Bureau